| アブストラクト | OBJECTIVE: To describe clinical outcomes of etonogestrel implant patients with migration to the vasculature, chest wall and other distant body sites spontaneously reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. STUDY DESIGN: We performed a standardized Medical Dictionary for Regulatory Activities (MedDRA) query in the FAERS database (through November 15, 2015), with reports coded with one or more MedDRA preferred terms that indicate complications with device placement or migration of the device from the original site of insertion to the vasculature, chest wall and other distant body sites. We excluded any cases previously described in the medical literature. RESULTS: We identified 38 cases of pronounced etonogestrel implant migration. Migration locations included the lung/pulmonary artery (n=9), chest wall (n=1), vasculature at locations other than the lung/pulmonary artery (n=14) and extravascular migrations (n=14) to other body sites (e.g., the axilla and clavicle/neck line/shoulder). The majority of cases were asymptomatic and detected when the patient desired implant removal; however, seven cases reported symptoms such as pain, discomfort and dyspnea in association with implant migration. Three cases also describe pulmonary fibrosis and skin reactions as a result of implant migration to the vasculature, chest wall and other distant body sites. Sixteen cases reported surgical removal in an operating room setting. CONCLUSIONS: Our FAERS case series demonstrates etonogestrel implant migration to the vasculature, chest wall and other body sites distant from the site of original insertion. IMPLICATIONS STATEMENT: As noted by the sponsor in current prescribing information, a key determinant in the risk for etonogestrel contraceptive implant migration appears to be improper insertion technique. Although migration of etonogestrel implants to the vasculature is rare, awareness of migration and education on proper insertion technique may reduce the risk. |
|---|
| ジャーナル名 | Contraception |
|---|
| Pubmed追加日 | 2017/9/5 |
|---|
| 投稿者 | Kang, Sarah; Niak, Ali; Gada, Neha; Brinker, Allen; Jones, S Christopher |
|---|
| 組織名 | Division of Pharmacovigilance II, Food and Drug Administration, 10903 New;Hampshire Ave., Silver Spring, MD 20993-0002, USA. Electronic address:;sarah.kang@fda.hhs.gov.;Hampshire Ave., Silver Spring, MD 20993-0002, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28867440/ |
|---|
